Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Puma Biotechnology
Biotech
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma landed a global license for $7 million upfront, plus up to $287.3 million in milestones, and plans to target breast and small cell lung cancer.
Nick Paul Taylor
Sep 21, 2022 9:05am
Seattle Genetics hails 'stunning' tucatinib breast cancer data
Dec 11, 2019 9:45am
Repurposing EGFR lung cancer drugs in leukemia
Sep 27, 2018 11:07am
FDA panel backs Puma’s neratinib, clearing path to approval
May 25, 2017 8:22am
Puma shares jump 40% after FDA review
May 23, 2017 5:07am
Ex-Puma exec charged with insider trading, hit with criminal charges
Sep 30, 2016 6:39am
